Six MASH biotech companies shaping the future of liver disease treatment

Summary

Labiotech.eu highlights six biotech companies developing MASH (metabolic dysfunction-associated steatohepatitis) treatments as the market for next-generation liver disease therapies expands. The article provides an overview of companies shaping the future of MASH therapy development.